The Circadian Clock in Cancer Development and Therapy - Progress in Molecular Biology and Translational Science - page 228

Table 9.1 Deregulation of the core clock genes in human cancers — cont'd

Circadian genes
deregulated Cancer type Deregulated targets Cellular functions affected References

Non-
Hodgkin's
lymphoma
(NHL)

Npas2 DMC1, EXO1, and MSH2 Cell cycle control, DNA

damage repair, and immune
deficiency

37, 70, 94

Diffuse large
B-cell
lymphoma

Bmal1 and
Clock

Catalase, c-MYC, and p300 Chromatin remodeling 75

Osteosarcoma CK1e and Per2 CASP3, Cyclin B, and Cyclin A2 Apoptosis and cell cycle

control

40, 95

Ovarian
cancer

Bmal1 , CK1e , Cortisol Apoptosis, cell cycle control,

and deregulated
chemotherapy drug response

39, 96, 97

Clock , Cry1 ,
Cry2 , Per1 ,
Per2 , and Per3

Pancreatic
cancer

Bmal1 , CK1e , BCL-XL, CDC2, Cyclin B1,

TNF- a , and USP30

Apoptosis, cell cycle control,
and chromatin remodeling

98-101

Clock , Cry1 ,
Cry2 , DEC1 ,
Per1 , Per2 , Per3 ,
Tim , and Tipin

Prostate cancer Bmal1 , CK1e , Melatonin, SIRT1, and TIP60 Apoptosis, cell cycle control,

DNA damage repair, and
transactivation of AR

35, 43, 45,
71, 102,
103, 104,
102-105

Clock , Cry1 ,
Cry2 , Npas2 ,
Per1 , Per2 , and
Per3